A Phase 1 interventional study of Adalimumab (BCD-057) and Adalimumab (Humira) in Healthy, sponsored by Biocad. Completed at 1 site in Russian Federation. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-05.
Sponsored by Biocad · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical study is a phase 1 study which carried out to establish the pharmacokinetic equivalence and equal safety and tolerability profile of BCD-057 (adalimumab biosimilar candidate manufactured by CJSC BIOCAD, Russia) and Humira when used as a single subcutaneous injection in healthy volunteers.
This is single center comparative double blind randomized clinical study of pharmacokinetics, tolerance and safety of single subcutaneous injection of BCD-057 (CJSC BIOCAD, Russia) and Humira in healthy volunteers. The purpose of the study is to demonstrate that BCD-057 is equivalent to Humira in terms of pharmacokinetics, tolerability and safety after single subcutaneous injection in healthy volunteers.
The study will enroll 94 healthy volunteers, who will be randomized into 2 groups (1:1 ratio): volunteers from the first group will receive BCD-057; volunteers from the second group will receive Humira. Both study and reference drug will be used at the standard dose of 40 mg.
Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
Drug: Adalimumab (BCD-057)
Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
Drug: Adalimumab (Humira)
Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
Also known as: BCD-057, Humira, Trudexa
Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
Also known as: Trudexa
Maximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira
Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity
Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours of Adalimumab After Single SC Injection of BCD-057/Humira.
Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Time to Reach Maximum Concentration of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira
Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Half-life Period of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira
Time frame: 0, 6, 24, 48, 72, 96,120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Volume of Distribution of Adalimumab After Single Administration of BCD-057/Humira
Time frame: 0, 6, 24, 48, 72, 96,120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Clearance of Adalimumab After Single Subcutaneous Injection of BCD-057/ Humira
Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
Elimination Rate Constant of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira
Time frame: 0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose
| Milestone | BCD-057 Group | Humira Group |
|---|---|---|
| Started | 47 | 47 |
| Completed | 40 | 44 |
| Not completed | 7 | 3 |
| Withdrew: Withdrawal by subject | 7 | 3 |
| ng/ml | BCD-057 Group | Humira Group |
|---|---|---|
| Maximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira | 4426 (3524 to 5902) | 4522 (3546 to 5104) |
| (ng/ml)*hour | BCD-057 Group | Humira Group |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity | 2488188 (1809194 to 2827564) | 2272029 (1815831 to 2904679) |
| (ng/ml)*hour | BCD-057 Group | Humira Group |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours of Adalimumab After Single SC Injection of BCD-057/Humira. | 2488187 (1809193 to 2778993) | 2272029 (1815831 to 2858812) |
| hours | BCD-057 Group | Humira Group |
|---|---|---|
| Time to Reach Maximum Concentration of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira | 120 (96 to 192) | 108 (90 to 150) |
| hours | BCD-057 Group | Humira Group |
|---|---|---|
| Half-life Period of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira | 263.35 (194.65 to 351.61) | 269.68 (196.29 to 317.01) |
| ml/kg | BCD-057 Group | Humira Group |
|---|---|---|
| Volume of Distribution of Adalimumab After Single Administration of BCD-057/Humira | 7165.85 (5105.07 to 8482.38) | 6622.06 (5637.07 to 7854.49) |
| ml/(h*kg) | BCD-057 Group | Humira Group |
|---|---|---|
| Clearance of Adalimumab After Single Subcutaneous Injection of BCD-057/ Humira | 16.08 (14.39 to 22.11) | 17.61 (13.99 to 22.04) |
| fraction of drug eliminated per hour | BCD-057 Group | Humira Group |
|---|---|---|
| Elimination Rate Constant of Adalimumab After Single Subcutaneous Injection of BCD-057/Humira | 0.003 (0.002 to 0.004) | 0.003 (0.002 to 0.004) |
Collected over 70 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BCD-057 Group | — | 0/40 (0%) | 9/40 (22.5%) |
| Humira Group | — | 0/44 (0%) | 14/44 (31.8%) |
| Event | BCD-057 Group | Humira Group |
|---|---|---|
| Elevated ALTHepatobiliary disorders | 3/40 | 11/44 |
| Elevated ASTHepatobiliary disorders | 3/40 | 3/44 |
| NeutropeniaBlood and lymphatic system disorders | 2/40 | 1/44 |
| MonocytosisBlood and lymphatic system disorders | 2/40 | 0/44 |
| MonocytopeniaBlood and lymphatic system disorders | 2/40 | 1/44 |
| HyperbilirubinemiaHepatobiliary disorders | 2/40 | 2/44 |
| LeucopeniaBlood and lymphatic system disorders | 1/40 | 2/44 |
Population for all type of analysis included 84 patients who received at least one study drug injection.
| Age, Categorical(Participants) | BCD-057 Group | Humira Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 40 | 44 | 84 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | BCD-057 Group | Humira Group | Total |
|---|---|---|---|
| Median | 24.5 (22 to 30.5) | 25.5 (22 to 29) | 25 (22 to 30) |
| Sex: Female, Male(Participants) | BCD-057 Group | Humira Group | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 40 | 44 | 84 |
The record gives a start of Jun 2015, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab